Jinsheng Medical Technology Co., Ltd. was established in 2021, led by Dr. Xia Dengning, who studied under Professor Mark Prausnitz, a member of the American     Academy of Engineering, and previously served as a research scientist at the Georgia Institute of Technology. The company is located on the 4th floor of Building 1, Hengtaiyu Building, South China Medical Valley, Guangming District.

    The company is committed to building a biomedical health industry service provider that integrates research and development, production, and sales of medical     biosynthetic technology, AI artificial intelligence protein analysis technology, protein modification technology, high-end microneedles, and long-acting microsphere precise delivery technology. The company develops high-end bio synthetic humanized collagen raw materials: Type I, III, I+III, XVII collagen, as well as application technology solutions for Type II, III implantable, adhesive, and puncture products. The product will be widely used in medical fields such as biomaterials, dermatology, medical beauty, bone transplant materials, and prosthesis transplantation.

    The project relies on years of experience and technology in structural biology, using human sequences and human expression systems, selecting key sites based on target functions, and developing humanized active collagen raw materials with a complete triple helix structure. Combined with current industry application pain points, the project develops biomaterials with good biological activity and fiber structure, as well as various raw material application technology solutions, which can promote product application technology solutions with single or multiple effects such as human skin support, skin moisturizing, whitening, collagen regeneration, anti-inflammatory and anti allergic, filling, bone repair, collagen transplantation, etc.

    The company has completed the research and functional testing of biosynthetic recombinant type III collagen raw materials, and type I, I+III, and XVII collagen are currently under development. The design and small-scale sample production trial of collagen application technology solutions such as microneedles, microspheres, and freeze-dried powder have been completed for terminal application technology solutions. Currently, the industrialization of recombinant type III collagen raw materials, equipment design for microneedles, microspheres, and freeze-dried powder production environment, and GMP workshop construction are underway. Relevant Class II medical device products are being registered, and Class III medical device subcutaneous implant filling products are undergoing preclinical research.

    The company will continue to conduct in-depth research and development on the industrialization, product application technology solutions, brand building, and market promotion of collagen raw materials such as recombinant type III, type I, type XVII, and I+III composite based on later project planning, in accordance with national medical device regulatory regulations.

    Enterprise official website: http://kingshinemed.cn/